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L ABSTRACT

Objective: To evaluate the accuracy of the Acute Physiology and Chronic
Health Evaluation (APACHE) II prognostic scoring system when applied to
human immunodeficiency virus (HIV) seropositive patients (with or
without the acquired immunodeficiency syndrome (AIDS)) in the Medical
Intensive Care Unit (MICU).

Methods: The medical records of all HIV-positive patients who were
discharged from the Yale-New Haven Hospital MICU between October 1, 1986
and September 30, 1991 were retrospectively reviewed and clinical and
laboratory data, including variables needed for APACHE II scoring, were
collected. Patients were assigned to disease categories using pre-determined
algorithms when documented clinical decisionmaking was unclear.

Results:

Records from 161 separate MICU discharges met the criteria for the

study. APACHE II greatly underestimated mortality among patients with
pneumonia (n=44) (28.5% estimated (E) vs. 50.0% observed (O), p < .005). In
the group of patients with pneumonia, APACHE II accurately predicted
mortality in patients with Pneumocystis cnrinii pneumonia (n=26) (28.2% (E)
vs. 34.6% (O)) but underestimated mortality in patients with pneumonia of
other or unknown etiology (n=18) (28.9% (E) vs. 72.2% (O), p < .005). In all
other patients (patients without pneumonia) (n=117), APACHE II correctly
estimated mortality (38.1% (E) vs. 41.9% (O')). In patients admitted to the
MICU with a diagnosis of infection (pneumonia or sepsis), a total lymphocyte
count (TLC) < 200 was a strong predictor of mortality. In all other patients
(without pneumonia or sepsis), TLC was not associated with outcome.
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Conclusion: The APACHE II prognostic scoring system is an effective method
of stratifying a general HIV-positive MICU patient population in respect to inhospital mortality, but it is not accurate when applied to a significant
proportion of our population, HIV-positive patients with pneumonia,
particularly non-Pneumocystis carinii pneumonia.

The reason for APACHE

II's underestimation of mortality is multifactorial. It is likely to be due, at
least partially, to (1) absence of adequate risk adjustment for severity of
immunologic suppression; (2) lack of precisely defined decisionmaking
algorithms to aid in the assignment of disease categories; and (3) a significant
proportion of HIV-positive patients with pneumonia of unknown etiology
who may be uniquely resistant to treatment. The use of TLC as an additional
risk factor may improve predictive accuracy of ICU risk adjustment models
for use in HIV-positive patients with diagnoses of infection.

IL INTRODUCTION

Beginning in the mid-1980's, the human immunodeficiency virus
(HIV) and the acquired immunodeficiency syndrome (AIDS) have had an
enormous impact on the American health care system and particularly on the
field of intensive care medicine. In 1990, there were an estimated one million
people infected with HIV in the United States.1 Of these one million people,
it has been projected that nearly 205,000 will have frank AIDS in 1993 and
nearly 246,000 in 1994.2 Many of these people with AIDS will need to be
admitted to an intensive care unit at some time during their illness.

Using

an estimate that the cost of treating all people infected with HIV will increase
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roughly 20% per year, it has been projected that $10.4 billion will be spent
treating all people infected with HIV in 1994 alone.2
Because AIDS has spread so rapidly and has affected such a great
proportion of the population, much research has been focused on elucidating
the pathophysiology of the human immune system and the role of
opportunistic infections in immunocompromised hosts.

In addition to

promoting basic science research, HIV infection and the "AIDS epidemic"
have led to greater discussion about the ethical dilemmas surrounding
quality of life decisions,3'14 and the aggressive medical treatment of patients
with serious and/or terminal illnesses.15'13 The healthcare system, and
society as a whole, is faced with difficult and interconnected ethical and
financial decisions. Physicians are being forced to do cost-benefit analyses in
addition to making the medical decisions for which they were trained. The
sort of decisions being made are variations on one simple question: "Is the
result worth the cost?" In other words, do the medical outcomes justify the
financial resources being spent?
This question must be considered in all medical settings and involving
all types of medical/financial decisions, ranging from state-funded childhood
immunization programs to organ transplant surgery. To answer these
questions, patient outcomes must be assessed and analyzed. Until recently,
however, the means to do this analysis have been lacking. Although the raw
data (mortality rates, nosocomial infection rates, surgical complication rates,
etc.) have been available, medical outcome analysis had proved to be difficult
to analyze since medical outcomes are dependent on a wide array of variables.
Medical outcomes are dependent not only upon the quality of medical care
but also upon other factors, including comorbid illnesses, access to care,
patients' extent of acute illness, and etiology of disease.
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One area of medicine in which cost-benefit discussions and medical
outcome analysis has become common has been in the intensive care setting.
In intensive care units (ICU's), prognostic stratification systems have been
developed to better analyze medical outcomes. The prognostic stratification
systems adjust for the variability of patient "case mix." In other words, these
systems are means of performing risk adjustment related to medical
outcomes. By accounting for varying degrees of patient "risk," these
prognostic systems allow more accurate outcome comparisons to be made and
facilitate cost-benefit analyses.
The most widely accepted system of risk adjustment in the ICU setting
is the Acute Physiology and Chronic Health Evaluation (APACHE) II
prognostic scoring system. Presently, however, APACHE II has not been
thoroughly evaluated in patients who are HIV positive or who have AIDS.
Thus, healthcare professionals are lacking the tools necessary to effectively
analyze medical outcomes in HIV-positive patients. Because a reliable
research tool is needed for outcome analysis in the increasing numbers of
HIV-positive patients, an evaluation of APACHE II's ability to perform risk
adjustment in HIV-positive patients was undertaken.

Before discussing the

current study and the recent literature pertaining to the application of
APACHE II to an HIV-positive patients population, understanding the
pertinent issues will be enhanced by briefly reviewing the field of prognostic
stratification and the development of the original APACHE and APACHE II
prognostic scoring systems.

Prognostic stratification
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Perhaps the easiest way to introduce the concept of prognostic
stratification is to consider the numerous ways in which it is used by
everyone in everyday life, on a minute-to-minute basis.

When an

automobile driver accelerates at a green light, when a baseball outfielder shifts
position for a left-handed batter, or when a diner orders a meal, prognostic
stratification is actively, though usually without awareness, being used. In
each of these "routine” daily circumstances, a decision is being made based on
past experiences in similar situations. The driver realizes that in the past
when he has been waiting at an intersection and the light has turned green, it
has usually, if not always, been safe to accelerate and cross the intersection.
The outfielder, probably with greater awareness of his mental processes,
recognizes, based on past experience (either his own or communicated by
others), that a left-handed batter is more likely to hit the ball toward right
field, and consequently, it would be wise to shift his field position accordingly.
The diner, preparing for a meal, remembers his own past dining experiences
(or those experiences told to him by friends), and orders based on expectations
of gustatory pleasure. In each of these circumstances, past experiences are
used to modify or make decisions in the present with an anticipated future
result.
Despite being done unconsciously or with little thought, each of these
hypothetical decisions is not simply based on vague, ill-defined recollections
and remembrances. Each person makes a decision based on past experiences
of similar circumstances or situations (a green light, a left-handed batter, or a
cheeseburger) being associated with another occurrence (driving safety, a fly
ball to right field, or enjoying one's meal). In effect, each decision is based on
nothing more than past associations and the assumption that past
associations will remain true and valid in the future. In other words, each
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decision in "routine" daily life is based on calculated probabilities arrived at
through past associations.
Thus, prognostic stratification is the process in which entities
(circumstances, occurrences, people, etc.) are placed into different strata based
upon past associations and future prognosis. This can be restated:
"Prognostic stratification is the process in which entities are placed into
groups with similar predicted results or outcomes."
Given the need in clinical medicine to base testing and therapy on
evidence of improved outcomes, it is no suprise that prognostic stratification
is used extensively in clinical medicine, and that medicine is, in fact,
dependent upon prognostic stratification. All medical decisions implicitly
utilize prognostic stratification.

When a physician discerns "baseline risk,"

considers different treatments based on the "clinical course" of a disease,
assigns cancer patients to different "stages," or chooses "appropriate"
antibiotic therapy for a presumed infection, he or she is actively grouping
(stratifying) patients according to outcome prediction (prognosis).
As discussed by Feinstein,19 prognostic stratification has three general
purposes in medicine: analytic, predictive, and explicative. In the first
instance, prognostic stratification can be used to reduce the effects of a
population's heterogeneity and "enhance the accuracy and efficiency of
statistical analysis"11' in one of two ways. Prognostic stratification can allow
for the avoidance of either false positive error or false negative error, and it
can improve the efficiency of statistical comparison of population groups.
False positive errors occur when "statistically significant" results are found
which are solely caused by the heterogeneity of the compared population
strata, not by true differences as measured by the test in question. Feinstein
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gives the following example19 of false positive error and the use of prognostic
stratification in avoiding this type of error:

Suppose we found that a group of 100 men with disease D had a 10-year
survival rate of 38%, whereas the rate was 62% for a group of 100 women with
the same disease. We might conclude that the disease had distinctly different
effects in men and women.
Now suppose, however, that patients with this disease could be
divided into a "good risk" prognostic stratum, with 80% 10-year survival, and a
"poor risk" stratum with 20% 10-year survival. Suppose further that the male
population contained 30 members from the good-risk stratum and 70 members
from the poor-risk stratum, but that these distributions were exactly reversed
in the female population. We would then find the following results for 10-year
survival rates:

Men

Women

Total

Good Risk

24/30(80%)

56/70 (80%)

80/100(80%)

Poor Risk

14/70(20%)

6/30(20%)

20/100(20%)

Total

38/100(38%)

62/100(62%)

100/200(50%)

On comparing results within the same prognostic strata, we would find
that the disease had exactly the same effects in men as in women: 80%
survival for good risks, and 20% survival for poor risks. Our original conclusion
about the disparate effects of the disease in men and women would have been
wrong because of the disproportionate distribution of the good-risk and poor-
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risk strata in the male and female cohorts. The male cohort was composed of
70% poor risks and 30% good risks, whereas the percentages were just the
opposite in the cohort of women.

Conversely, false negative errors occur when "statistically significant" results
are not found (or are hidden) due to the heterogeneity of the compared
population strata.
Prognostic stratification improves the efficiency of statistical
comparison by identifying "polar strata," (those members of a population
who are either extremely likely or unlikely to attain the specific result being
considered). If allowed to remain unidentified, members of the "polar strata"
will mix in with the total population, thereby diluting the test's results and
producing inefficient statistical comparison.

In addition, the identification

and separation of "polar strata" is especially important in the testing and
analysis of therapeutic claims. For example, in investigating a new treatment
for cancer, it is extremely difficult to prove that the new treatment is either
effective or ineffective. Oftentimes, in order to produce statistically
significant results, inordinately large (and financially constraining)
population sample sizes must be employed. In this situation, a polar stratum
is an ideal population to use as a test population because a polar stratum, by
definition, is either extremely likely or unlikely to attain a specific result and,
therefore, the predicted result will have a small calculated standard error and
a narrow confidence interval (ranging between two standard errors below and
above the mean). Consequently, by testing the new treatment on a polar
stratum, statistical significance or insignificance can be more easily
determined.
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The second general purpose of prognostic stratification is predictive.
The manner in which prognostic stratification can "enhance confidence in
the predictive decisions of clinical practice"19 has been mentioned but
deserves to be discussed more thoroughly. One way in which prognostic
stratification can improve predictive accuracy is by allowing clinicians to base
current prognosis on the outcome of past patients who were in the same
prognostic stratum as the present subject. Second, prognostic stratification
can improve therapeutic decisionmaking by allowing physicians to choose
treatments which have been tested and have proven results on patients with
the same attributes as the present patient. This use of prognostic stratification
is directly applicable to patient-specific decisionmaking concerning the
initiation or withdrawal of life-sustaining or life-prolonging therapies.

For

example, extremely low birthweight infants with a zero percent survival
probability usually will not have heroic therapy initiated. Third, the design of
therapeutic trials can be refined by dividing the study population into
distinctive prognostic strata prior to comparing tested treatments. This can be
done to improve either randomized or nonrandomized trials and is
especially important in nonrandomized trials when stratification is the main
method available to reduce bias.
A third use of prognostic stratification is "to demarcate observed
phenomena in a manner that allow them to receive a scientific
explication."19 In other words, prognostic stratification is useful for
explaining the variability or variance of observed outcomes. With the
current political and administrative emphasis on cost control and resource
allocation (ICU utilization, nursing care staffing, patient triage decisions), this
ability of prognostic stratification to explain the variance of outcome
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measures is becoming especially important and useful in health care research,
decisionmaking, and the evaluation of medical care quality.
Prognostic stratification is able to explain the variance of outcomes by
what has been termed "risk adjustment" or "case-mix adjustment."

By

dividing a heterogeneous patient population into groups (strata) with similar
medical expectations (prognoses), prognostic stratification can reduce the
uncertainty inherent in comparing outcome measures and allow a more
meaningful comparison and explanation of observed outcomes.

Without

prognostic stratification, any differences in target events (ie., observed
mortality rates, infection rates, etc.) can not be ascribed to actual differences in
the process being measured. "[T]he compared maneuvers may appear to give
different results; but the real difference may arise only from disproportions in
the strata that constitute the cohort."20
Outcome comparisons can be made at three organizational levels:
between individuals, between groups of people, or between institutions.
Temporal comparisons can also be made: comparing outcome data from the
same individual, group, or institution during different time periods.
Although some outcome measures are more commonly analyzed in specific
situations (ie., mortality rates at an interinstitutional level, surgical success
rates at an individual level), any one outcome measure can be analyzed at any
organizational level, and the inherent uncertainty of all outcome
comparisons is reduced by means of prognostic stratification. In fact, outcome
analysis is virtually dependent upon prognostic stratification for the
meaningful interpretation of results.
The most common method of using prognostic stratification for the
explication of outcome variance involves the development of prognostic
scoring systems. These scoring systems can be and have been applied to a

11

variety of clinical conditions (discussed below). Despite the varying
applications of these systems, they are all generally predicated on the same
analytic formulations and are, consequently, very much alike. The analytic
model which is followed is based on mathematical functions called additive
value functions. Though a detailed analysis of additive value functions is
beyond the scope of this paper, a short description of the foundation of these
functions is worthwhile.
Additive value functions, as discussed by Krischer,21 are special
instances of mathematical formulae designed to quantify the relative
importance that one attribute makes toward a general condition. In the
health sciences, they are generally expressed in the form of an equation:

V (Xi, X2.Xn) = V! (X]) + V2 (X2) + ... + Vn (Xn)

where V is the prognostic score, X], X2, ..., Xn is a list of medical attributes that
describe a person, and Vi, V2, ..., Vn are numerical descriptions of the relative
importance or "weight" of each attribute. In terms of clinical prognostic
stratification, additive value functions are designed to quantify the relative
importance that each medical attribute makes toward general clinical
prognosis. The form of this equation implies one important point.

Namely,

that each medical attribute included in the equation has a contribution to the
formulation of medical prognosis, and is independent of the contributions
made by the other medical attributes.
One specific type of prognostic scoring system has been termed a
severity of illness index. Like all prognostic scoring systems, severity of
illness indices strive to group patients based on known attributes, and are
analytically formulated on additive value functions.

Severity of illness
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indices are becoming increasingly popular in medical care for two reasons.
First, the capacity to do the complex data analysis required by sophisticated
severity of illness index software has increased dramatically during the last
decade. And second, as political and economic attention has been
increasingly focused on the current "health care crisis"in the United States,
more data has been necessary for outcome comparisons. In keeping with the
growing emphasis on outcome comparisons and "case-mix" data needed for
such comparisons, severity of illness indices will be the focus of the
remainder of this paper.
Because severity of illness indices are a specific class of prognostic
scoring system and are based on additive value functions, an obvious
question arises concerning the formulation of indices: "How are the specific
medical attributes (Xi ... Xn) and their relative importance (V] ... Vn)
determined?" There are basically two methods to accomplish this task.

One

is to base the determination on clinical judgement; the other is to base the
determination on statistical methods of analysis. Oftentimes, a severity of
illness index will be created based upon clinical judgment, and later refined
based upon statistical analysis.
As reviewed in a report by the Institute of Medicine,22 three methods
of formulating group judgment exist. The three methods are extremely
similar in that they all use subjective and arbitrary assessments to form the
basis of their decisions. They only differ on the manner in which the final
group judgment is formulated. One method, the Delphi technique, arrives at
its final formulation based a survey process of isolated, non-interacting,
participants.

The survey process elicits anonymous opinions from members

of a selected expert group by formal questionnaire or individual interview.
Summarized anonymous feedback is then provided to the group members
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and opinions may again be elicited. The group response is formulated by
aggregation of the individual opinions during the final round of questioning.
The major advantage of the Delphi technique is that the participants are not
in direct contact with one another, and, thus, "variables of professional status
and personality have little chance to influence opinions as they might in faceto-face meetings...."22 Conversely, the major disadvantage of the Delphi
technique is that the opportunity for the clarification of ideas among
participants is lacking.
Nominal group technique (NGT), differs from the Delphi technique in
that the participants are not isolated from one another. Using NGT,
participants express their opinions anonymously (either by writing or by
computer terminal), and the opinions are considered by the group.
Clarification of opinions may be given (also anonymously). Further rounds
of iteration and clarification of opinions may be used as needed. The final
formulation of group judgment is established by anonymous voting or
ranking. The advantage of NGT, like the Dephi technique, is that effects of
personal status and group hierarchical structure are minimized. However,
NGT is superior over the Delphi technique in that it allows for the
clarification of ideas among participants.
The third method of arriving at group judgment is the consensus
method.

The hallmark of the consensus method is its reliance on open

discussion among participants who know one another.

Consensus

conferences, employed by the National Institutes of Health, are characterized
by an initial presentation of information, followed by open discussion, then
the drafting of consensus answers, further discussion and comments about
the consensus answers, and incorporation of the comments in a final
consensus statement. Obviously, the consensus method does not limit the
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influence of social, personal, or hierarchical factors on the formulation of the
final group judgment. However, it may encourage discussion to a greater
extent than NGT.
In contrast to the use of group judgment, methods of statistical analysis
use objectively derived information as the basis for the inclusion of attributes
and their relative importance within the severity of illness index.

The

relevant information is derived from multivariable analysis to determine
"statistically significant" associations between attributes and outcomes. After
these determinations are made, statistically significant variables are included
within the index, with their relative importance correlated to the degree of
their statistical significance. The analysis is most commonly done by one of
two methods: either multiple logistic regression or by proportional hazards
regression (also known as Cox regression). Although a detailed description of
these methods of statistical analysis are beyond the scope of this paper, they
are covered in standard textbooks on statistics and have been thoroughly
discussed in a recent journal article).23
Though statistical analysis is the more superficially credible method
(due to its mathematical rigor) in the development of severity of illness
indices, some of the most widely accepted indices were developed using
clinical judgment as the sole means of deriving the indices' formulations.
One of the most widely recognized and used severity of illness indices is the
Apgar Score. This index was developed in 1953 for the evaluation of
newborn infants using subjective clinical judgment to create the
mathematical formulation of the index.

Another clinically derived index

which has attained broad acceptance and use is the Glascow Coma Score
which was designed to quantify degree of brain injury and improve
prognostic accuracy in affected patients.
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Beginning in the early 1970's and continuing through the 1980’s, as
computer data analysis capacity increased and as the field of health care
administration and research increasingly focused attention on the need for
more reliable and objective means of analyzing health care outcomes, greater
numbers of severity of illness indices were developed. Some indices were
created for patients with specific diseases (burns, liver disease, schizophrenia,
gastrointestinal hemorrhage, sepsis, scleroderma, drug overdose, acquired
immunodeficiency syndrome, etc.). This has been evident especially
concerning cardiac disease.24*30 Other indices have been designed specifically
for certain patient groups. Patients with injuries from trauma and, in
particular, automobile-related trauma have been the subject of many severity
of illness indices (Figure l).31*37

Figure 1: Early Trauma Indices

Abbreviated Injury Scale (1971)31
Trauma Index (1971 )32
Comprehensive Injury Scale (1972)33
Injury Severity Score (1974)34
Modified Trauma Index (1974)33
Triage Index (1974)'3^
Estimated Survival Probability Index (1978)37

As briefly mentioned before, one area of health care in which health
care researchers have fashioned numerous severity of illness indices in the
intensive care unit (ICU) (Figure 2).33-43 This is so for numerous reasons. For
one, intensive care units (ICU’s) are increasingly used as the treatment setting
of choice for critically ill patients. Beginning in the 1960’s as hospital centers
for emergency cardiac care, ICU’s have spread rapidly. By the mid-1970's, as
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prognostic scales were proliferating, it was reported that seven out of every
one thousand patients were transferred to an ICU for specialized care, and it
was projected that nationally over seven million patient days were spent in
ICU's annually.39

Figure 2: Intensive Care Treatment Indices

Therapeutic Intervention Scoring System (1974)3<s
Condition Index Score (1981 )39
Acute Physiology and Chronic Health Evaluation (APACHE) (1981 )49
Simplified Acute Physiology Score (1984)41
Mortality Prediction Model (1985)43
APACHE 11 (1985)43
Organ System Failure Based Model (1991)44
APACHE III (1991 )45

Second, ICU’s are the most costly site of medical care because they are
the main locus in which acute, technologically advanced and expensive care
is given. Heroic, life-sustaining treatment is readily available and is often
used in ICU’s to keep patients alive while in the midst of their acute illness.
This fact, coupled with the large volume of patients who are treated in ICU’s,
accounts for the exponential growth of ICU expenditure. In 1992, intensive
care services cost approximately 62 billion dollars and accounted for nearly 8%
of projected national health care spending46 and approximately 1% of the
United States' GNP.47 Because of the vast quantities of money being spent in
ICU's, it became imperative that cost-efficient diagnosis and treatment plans
be developed through risk adjusted outcome assessment.
A third reason that intensive care was well suited for prognostic
stratification research was that ICU outcomes were known to vary widely
between different ICU's, but little was known as to the cause of the variation.
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One review article reported mortality rates in surgical ICU's to range from 2%
to 44%.4^ With the tools available in the late 1960’s and early 1970's, it was
impossible to ascertain whether this outcome variation was due to differences
in therapeutic efficiency (the quality of the medical care) or the differences in
patient case mix (the degree of initial severity of illness and comorbidity).
Fourth, intensive care was (and still is) characterized by a great degree
of patient monitoring, laboratory use, and the routine daily collection and
recording of a large amount of detailed clinical information. Consequently,
researchers interested in medical outcome analysis had a large amount of
readily available data with which to develop more sophisticated predictive
models to measure patient case mix.
Consequently, due to the combination of these four characteristics of
intensive care medicine (a large volume of patients, an exponentially
increasing use of financial resources, great variance in medical outcomes, and
readily available clinical and laboratory data), medical outcome research was
focused on intensive care from an early date. In this setting, many research
tools were developed to allow a more meaningful evaluation or analysis or
intensive care data. Many prognostic scoring systems and severity of illness
indices were developed with the purpose of explaining some of the variance
known to exist in intensive care outcomes and allowing risk-adjusted
comparisons of medical outcomes.

APACHE

One index which was designed to help explain the variance of
outcomes in ICU’s is the Acute Physiology and Chronic Health Evaluation

1

I
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(APACHE) prognostic scoring system.40 This prognostic system was
developed by William A. Knaus, M.D. and colleagues at the George
Washington University Medical Center. In 1978, with a grant by the U.S.
Health Care Financing Administration (HCFA), Knaus et. al. began
developing APACHE to provide "an improved method for estimating the
pretreatment risk of death of acutely ill hospitalized patients...."44 In other
words, one of the purposes of the APACHE system was to provide a means to
improve clinical prognostic accuracy.
In addition to its predictive function, APACHE was designed with an
explicative purpose. APACHE was designed to explain outcome variance
(differences in in-hospital mortality rates) by "adjusting" for the patients'
initial composite severity of illness. Thus, APACHE could provide an
objective means to assess patient care outcomes at different institutions or
within the same institution at different points in time or among different
patient groups. Knaus and his colleagues felt that APACHE could have
analytic use by improving "the ability of nonrandomized study designs to
produce convincing evidence of efficacy."40 The essence of the APACHE
severity of illness index was that it could objectively quantify the degree of
patient illness, and thus, could provide "an answer to the nagging question of
most nonrandomized studies: 'Were the two patient groups similar?'"40
The conceptual approach of APACHE toward measuring a patient's
severity of illness included two areas of assessment: a physiological score
representing acute illness and a preadmission health evaluation indicating
health status before acute illness. The acute physiology score (APS) was
calculated by measuring the most abnormal value of each of thirty-four
physiologic variables (blood pressure, heart rate, serum pH, serum sodium,
etc.) during the first thirty-two hours of ICU admission. Each variable and its
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relative influence on the APS were determined by consensus methods. The
variables were chosen to represent a derangement in one of the body's seven
major physiological systems (neurological, cardiovascular, respiratory,
gastrointestinal, renal, metabolic, and hematological) and were assigned a
weight ranging from zero to four depending on the degree of derangement:
the more abnormal the measured variable, the greater the weight assigned.
Because the APS was solely the sum of the measured variables, it followed
that the more abnormal the measured variables, the higher would be the
APS, thus representing a more acutely ill the patient.
The second area of assessment, the preadmission health status, was
included within APACHE so as to differentiate patients with similar acute
physiology, yet with different abilities to "fight off death" and recover. In the
original APACHE this assessment was based on the patient's functional
status, productivity, and degree of medical attention sought six months prior
to admission. The patient was assigned a letter designation (A, B, C, or D) to
correspond to a physiologic reserve ranging from good prior health (A) to
severe restriction of activity due to disease (D).
Although APACHE was a fairly reliable means of stratifying ICU
patients according to their severity of illness and risk of subsequent hospital
death, APACHE proved to be too complex for routine clinical use.49
Consequently, Knaus and colleagues reevaluated APACHE, made some
necessary changes, and called the modified system APACHE II (Figure 3).
Whereas the original APACHE score was based on two components (the APS
and the preadmission health status), the APACHE II score was the numerical
sum of three components:

APACHE II Score = APS + Age points + Chronic Health points.
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In the area of assessing the degree of acute illness, the APACHE acute
physiology score was judged to incorporate too many physiologic variables,
some of which were not routinely measured (serum osmolarity, serum lactic
acid, skin anergy testing, etc.) or added little explanatory power (ie., serum
glucose, urinary output, albumin,).43 By using a combination of consensus
methods (based on clinical judgment) and methods of statistical analysis, the
thirty-four APACHE variables were reduced to twelve to form the APACHE II
APS. Another change to the APS consisted of revising the weighting system.
Although most variables were weighted in the same manner as before (from
zero to four, with a weight of four signifying the greatest physiologic
derangement) three variables were given different calculation parameters,
namely, serum creatinine during acute renal failure, the Glascow coma score
as a measure of neurologic function, and oxygenation assessment was
quantified with consideration of inspired oxygen concentration (FiCb). As
well, in a slight change from the original APACHE system, the recorded value
of each physiologic variable was based on the most abnormal reading during
the patient’s first twenty-four (instead of thirty-two) hours in the ICU.
The assessment of prior health status, though conceptually the same as
in the original APACHE, was more specifically defined. The new system's
prior health assessment considered patient age (a graded scale ranging from
zero to six, with advanced age being accorded more points), and chronic
health evaluation.

The chronic health evaluation was based on both chronic

organ system insufficiency (either hepatic, cardiovascular, respiratory, renal,
or immunologic) and operative status (nonoperative, emergency
postoperative, or elective postoperative).
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The major modification incorporated into the APACHE system was a
classification of disease process. This was done with the realization that
patients with equal acute physiologic derangement but with different
pathophysiologic processes are clinically expected to have unequal mortality
risks. As an example: two patients, both with identical pathophysiologic
abnormalities (poor oxygenation and acidemia) are admitted to the ICU for
respiratory support. One patient is admitted due to asthma; the other due to
an advanced lung neoplasm.

Although their acute physiologic derangements

are identical, these patients have significantly different probabilities of dying.
Because the latter patient has a much more life threatening disease, his risk of
death is much higher. In order to incorporate this reasoning, the modified
APACHE assigned each patient to a diagnostic category and assigned each
diagnostic category its own weighting used to predict mortality.
The APACHE II scoring system retained the same conceptual
framework of the original APACHE system in that each patient's total
APACHE score was computed by summing the APS, the age points, and the
chronic health points. The range of possible APACHE II scores is from zero to
seventy-one with a higher score associated with a greater likelihood of death.
At the time of original publication describing the APACHE II system, the
highest actual patient score recorded was fifty-five. Although the APACHE II
score could be used for patient classification and stratification within
treatment groups, it alone could not be used to predict medical outcomes
(death versus survival). The APACHE II score was only one factor used in
the calculation of predicted mortality risk.
APACHE II was able to prognosticate in-hospital mortality rates by
incorporating disease process classification into its patient assessment.
Specifically, APACHE II placed patients into one of fifty-three diagnostic
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categories (twenty-nine being nonoperative, and twenty-four being
postoperative) according to the reason for ICU admission. Each category was
assigned a diagnostic category weight (DCW), and predicted risk of subsequent
hospital death could be calculated by using the following multiple logistic
regression equation :

In (R/l-R)= -3.517+ .146 (APACHE II score)+ DCW + .603 {only if
emergency postoperative},

where R is the risk of death.

It should be noted that the APACHE II system of risk prediction,
though based on an equation used to predict mortality risk for individual
patients, was not designed to be used for individual patient risk prediction.
The APACHE II was developed to predict mortality risk for groups of patients.
(Individual patient prognosis was felt to be an unrealistic goal for two
reasons: one, because of the great variation among individual patients in
terms of hospital course and pre-existing disease, and two, because
"physicians are ... reluctant to accept estimated probabilities as the basis of
limiting or stopping treatment."40 (In order to maintain the accuracy of
APACHE II, it was suggested that disease-specific mortality predictions must
be derived on a minimum of fifty patients in each diagnostic category, with at
least twenty patients in the least frequent outcome category.) Though not
designed to substitute for clinical judgment regarding individual patient
outcome prediction or treatment decisions, APACHE II could be used as a
source of information for clinicians and as a tool for analysis of medical
outcomes. As well, it should be realized that APACHE II was designed as a
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means of prospective health assessment and risk stratification. Thus,
APACHE II measurements (physiologic variable readings) and classification
decisions (placement of patients into disease categories) were made on a real
time basis without the advantage of hindsight.
The APACHE II prognostic scoring system was validated in a study of
5,815 ICU admissions at thirteen different hospitals.43 A direct relationship
between APACHE II scores and observed hospital mortality rate was found to
be statistically significant through the entire range of scores (greater APACHE
II scores were associated with higher mortality rates). Direct cross-tabulations
and multivariate techniques were used to compare the predictive power of
APACHE II with the original APACHE system and examine the relative
importance of the components of APACHE II. This analysis showed that
APACHE II had better explanatory power than the original APACHE as
measured by model chi-square, percent of cases correctly identified, R-squared,
rank correlation between outcome and predicted probability, and area under
ROC curve (Table 1). The overall correct classification rate (classifying
patients as either predicted to die or predicted to survive) was eighty-six
percent (using a predicted mortality cutoff point of 0.50) (Table 2).
In general, APACHE II has been quite a success as is evident by its
widespread use by other researchers. The APACHE II system has been
incorporated into independent studies, in research related to both clinical
decision-making and health policy.7>49 As well, in the clinical realm of
medicine, hospitals have used APACHE II within their ICU’s as the basis for
utilization and outcome-based quality management programs, and some
foreign countries have even adopted APACHE II as the prognostic scoring
system in all of their ICU’s.49
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Table 1: Measures of Aggregate Explanatory Power
APACHE 11

APACHE*

1537.1

1634.5

R-squared

.310

.319

Rank correlation (between
outcome and predicted probability)

.730

.739

Area under ROC curve

.851

.863

Model Chi-square

Data presented in "APACHE II: A Severity of Disease Classification System" by
Knaus et. al.

Table 2: Outcome Classification (APACHE vs. APACHE II)
APACHE*
(N=582)

APACHE II
(N=5030)

Sensitivity (%)

49.0

47.0

Specificity (%)

97.3

94.9

PPV (%)

79.4

69.6

NPV (%)

90.0

87.9

Correct (%)

88.8

85.5

A cutoff of 0.50 was used to divide the two predicted groups. Calculated mortality risk
> 0.50 implied predicted death; calculated mortality risk < 0.50 implied predicted
survival.
Data presented in "APACHE II: A Severity of Disease Classification System" by
Knaus et. al.
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However, despite widespread utilization of APACHE II by independent
research groups, there still exists some controversy about its role in case-mix
risk adjustment, severity of illness stratification, and mortality prediction.
There have been both prospective and retrospective studies of APACHE II's
utility when applied to specific patient groups or as compared to other
prognostic scoring systems. APACHE II has been studied in regard to patients
receiving total parenteral nutrition,50 patients with cardiogenic pulmonary
edema,51 with hematologic malignancies,52 with perforated ulcers,55 with
acute pancreatitis,54 with breast cancer,55 after cardiac arrest,56 with acute
trauma,57 with intra-abdominal abcesses,58 and (as will be discussed below) in
patients with acquired immunodeficiency syndrome (AIDS).59'62 Several
studies highlight APACHE II's lack of advantage over clinical judgment in
terms of predictive accuracy,63'65 while another study brings attention to the
lead-time bias (caused by measuring patients attributes at varying times,
including after initiation of therapy) inherent in the APACHE II system.66
One research group documented APACHE II's inaccuracy in predicting
surgical ICU parameters such as length of stay and total hospital costs,67
though this should not be suprising since APACHE II was designed to predict
and explain mortality rates, not utilization measures.
Although these numerous publications have pointed out APACHE II's
failings, they are, at the same time, a reference to APACHE II's strengths as a
prognostic scoring system and act as testimony to the importance APACHE II
has achieved in the field of outcome prediction, risk stratification, and quality
management.

I

i
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Prognostic stratification in patients with AIDS or HIV seropositivity

Many publications concerning patients with AIDS have focused on the
relationship of patient attributes (CD4+ T-cell counts, method of HIV
infection), diseases, and therapies. Much of the outcome research on patients
with AIDS has been directed primarily on the documentation of mortality
rates and the determination of prognostic factors. Numerous papers have
documented the outcomes of patients hospitalized with AIDS, most especially
patients with Pneumocystis carinii pneumonia (PCP). In the early years of the
AIDS epidemic (before 1988), studies consistently reported poor survival rates,
particularly in patients with respiratory failure necessitating mechanical
ventilation. Most of these patients had PCP, and reported mortality rates
ranged from 86% to 100%/5,6,9,68,69 \n 1988, mortality rates were noted to
drop. One study reported mortality among patients with first episodes of PCP
to be 58%.8 Since this initial report of improved outcome, three studies have
reported in-hospital mortality rates (in AIDS patients with pneumonia
requiring mechanical ventilation) that confirm this lower mortality rate.4'7'16
Following this trend in improved in-hospital survival in AIDS
patients with pneumonia (either due to P. carinii or another pathogen), out¬
patient survival rates were reported to be improving as well. In 1990, two
reports documented improved short-term (1-year) out-patient survival rates
from 1984 through 1987.Hdi By 1991, in a study of AIDS patients who were
admitted with acute respiratory failure due to PCP between January 1, 1987
and December 31, 1990, in-hospital mortality was 53% and 1-year mortality
was 63%.13
In addition to longitudinally tracking mortality rates, researchers have
focused their attention on the elucidation of prognostic factors for patients
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with AIDS. Numerous clinical and laboratory variables have been
documented to have prognostic value in stratifying AIDS patients. In 1987,
Brenner et. al.12 linked poor outcomes in patients with PCP to five
determinants:

(1) severe abnormalities on initial chest radiographs, (2)

alveolar-arterial oxygen gradient (AaPO?) greater than 30 mm. Hg, (3) severity
of interstitial edema on initial transbronchial biopsy, (4) the persistence of
Pneumocystis cysts on follow-up biopsy, and (5) diagnosis of PCP before July,
1985. Brenner et. al. also reported that total leukocyte counts has no
prognostic significance for either acute or long-term life expectancy.
In 1988, El-Sadr and Simberkoff8 reported that survival of patients with
PCP was predicted by a constellation of clinical and laboratory findings: a short
duration of symptoms (most commonly shortness of breath, cough, fever,
chest pain, and weight loss), better arterial oxygenation on admission, and a
decrease in serum lactate dehydrogenase (LDH) and an improvement in
arterial blood gas determinations after institution of mechanical ventilation.
In 1991, Peruzzi et. al.70 reported that, in patients with PCP, the presence of
metabolic acidemia (a pH < 7.35 and a base deficit > 4 mEq/L) and prolonged
positive end-expiratory pressure (PEEP) > 10 cm. H2O were poor prognostic
signs.

Peruzzi et. al., in disagreement with Brenner et. al., reported that chest

radiographic findings did not predict mortality in this group of patients.
Serum LDH was determined to be of prognostic value in patients with
PCP by several groups of researchers. In 1988, Lipman and Goldstein71
presented evidence that serum LDH in PCP patients had high prognostic
value. Serum LDH values greater than 520 IU had a 100% sensitivity of
predicting death and a specificity of 61%. These results were confirmed by two
groups of researchers. Kagawa et. al., though primarily studying the use of
serum LDH in the diagnosis of PCP, concluded that serum LDH "correlates
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with the severity of [PCP patients'] oxygen transfer disorder."72 Garay and
Greene determined that serum LDH levels, AaPCb gradients, and mean
respiratory rates had prognostic value for patients with PCP.77
Of note, Garay and Greene found no significant difference between PCP
survivors and nonsurvivors "with respect to duration of symptoms, presence
of physical findings (other than respiratory rate), and admission leukocyte or
lymphocyte counts."73 This is in agreement with Brenner's findings
concerning leukocyte counts and in disagreement with El-Sadr and
Simberkoff’s results concerning symptom duration.
Besides the determination of individual prognostic factors for patients
with AIDS (predominantly with PCP), two separate prognostic scoring
systems have been developed for patients with AIDS. The AIDS Prognostic
Staging System,74 created by Justice and Feinstein in 1989, was designed to
stratify hospitalized and non-hospitalized AIDS patients according to
predicted long-term mortality.

The system, developed and tested on a cohort

of 117 AIDS patients between October, 1981 and July, 1987, divides patients
into three stages based on four potential forms of physiologic deficit:
nutritional, respiratory, neurologic, or hematologic. One point is given for
each of the following: severe diarrhea or serum albumin < 2.0 g/dl, any
neurologic deficit, arterial oxygen tension < 50 mm Hg, hematocrit < 30
percent, lymphocyte count < 150/gl, white blood cell count < 2500, and
platelet count < 140,000 (Table 3). The total score determines the assignment
of stage: Stage I (0 points). Stage II (1 point), and Stage III (2 to 7 points). In so
far as the initial cohort of 117 patients with AIDS, the AIDS Prognosis score
proved to be a reliable means of stratifying patients according to out-patient
mortality: patients in Stages I, II, and III had median survival times of 11.6,
5.1, and 2.1 months, respectively.
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Table 3: The AIDS Prognosis Score

Characteristic

Points Awarded

Nutritional
— Severe diarrhea and/or
serum albumin < 2.0 g/dl

1

Respiratory
-- P02 < 50 mm Hg

1

Neurologic
— Any manifestation

1

Hematologic
— Lymphocytes < 150

1

— Hematocrit < 30%

1

— White blood cells < 2,500

1

— Platelets < 140,000

1

The second AIDS-specific prognostic scoring system developed was the
PCP Severity Score (PSS).75 Created by Speich et. al. in 1990, the PSS was
developed on a cohort of 59 nonintubated PCP hospitalized patients. It was
designed to stratify this group of patients according to mortality within 14
days aftPr bronchoscopy. The score is constructed by the degree of abnormality
of three measures: alveolar-arterial oxygen gradient (AaPO?), serum LDH,
and percentage of brochoalveolar lavage (BAL) neutrophils (Table 4). These
variables were chosen by statistical analysis and is in agreement with many of
the previously discussed reports. Variables which were found to have no
statistical significance included duration of symptoms, hemoglobin, total
leukocyte and lymphocyte counts, and C-reactive protein. It should be noted
that Speich et. al.'s finding that total leukocyte and lymphocyte counts are
not prognostically significant are in agreement with the results reported by
Garay and Greene but are in disagreement with those reported by Justice and
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Feinstein. However, the disagreement between these results could be a
function of the different outcomes being measured (14 day mortality versus
long term mortality). The PSS was validated in 1992 in a prospective
evaluation of 94 patients with PCP. In this follow-up validation study, the
PSS displayed an overall diagnostic accuracy of 95.7%.

Table 4: The PCP Severity Score
Points
1
2
3
4
5

AaPCb (mm Hg)
> 20
> 30
> 40

LDH (U/l)

BAL neutrophils (%)

> 460
> 920
> 1,380

>2

> 50
> 60

>5
> 10
> 15
> 20

As reviewed above, although AIDS-specific prognostic scoring systems
have been developed and numerous prognostic factors have been
determined, there is disagreement concerning the validity of individual
prognostic factors. Therefore, the utility of these systems and factors is
limited.
In contrast to the AIDS-specific scoring systems mentioned above, the
APACHE II prognostic scoring system has been used extensively and
independently validated. However, because APACHE II was devised before
the rapid spread of HIV infection, the accuracy of APACHE II in respect to
patients with AIDS is open to question.

By September 1990 (the date of

inception of the current study), only one research group had published results
of applying APACHE II to patients with AIDS.
Smith et. al. published the results of their research in October 1989.59
Analyzing data collected retrospectively from the medical records of 83 MICU
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patients with AIDS admitted between January 1984 and September 1988, they
found that APACHE II significantly underestimated in-hospital mortality
(45.8% (E) vs. 63.9% (O)) (Table 5). The inaccuracy of the APACHE II mortality
prediction was shown to be due solely to an underprediction of mortality in
patients with Pneumocystis carinii pneumonia (PCP) requiring mechanical
ventilation. In patients with PCP (n=37), predicted mortality was significantly
less than observed mortality (44.3% vs. 86.5%), whereas in all other AIDS
patients without PCP (n=46) predicted and observed death rates were similar
(47.0% vs. 45.7%). The similarity of predicted and observed mortality rates
extended to AIDS patients without PCP who required mechanical ventilation
(n=17) (72.3% vs. 76.5%) and AIDS patients without PCP who did not require
mechanical ventilation (n=22) (31.6% vs. 36.4%).

Table 5: Comparison of APACHE II Predicted and Observed Mortality (Smith et. al.)

Predicted Mortality

Observed Mortality

Group

Rate, %

Rate, %

All Non-AIDS (n=166)
Mech vent (n=25)

34.1
48.1

31.3
52.0

45.8

63.9

44.3

86.5

Not mech vent & PCP (n=46)

47.0

45.7

Mech vent, non-PCP (n=17)

72.3

No mech vent, non-PCP (n=22)

31.6

76.5
36.4

Total AIDS (n=83)
Mech vent & PCP (n=37)

Also, it was reported that mean APACHE II scores did not differentiate
survivors from nonsurvivors (22.8 vs. 26.0) nor differentiate survivors from
nonsurvivors in the subset of mechanically ventilated patients with PCP (23.4
vs. 22.3) (Table 6). However, when the subset of mechanically ventilated
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patients with PCP was excluded, APACHE II successfully differentiated
survivors from nonsurvivors (22.6 vs. 31.6).

Table 6: Comparison of APACHE II Scores Between Survivors and Nonsurvivors (Smith et. al.)

Group

Survivors

Nonsurvivors

p Value

All non-AIDS

15.5 ±7.0

27.2 ± 8.6

< 0.01

All AIDS

22.8 ± 5.7
23.4 ± 4.0

26.0 ± 9.1
22.314.7

> 0.05

22.6 ± 6.1

31.6 ± 11.3

< 0.01

Mech vent & PCP
All other AIDS

NS

Smith et. al. explained that the discrepancy between predicted and
observed mortality rates in patients with PCP (and, by extension, in the entire
AIDS population) is most likely due to the lack of a specific APACHE II
diagnostic category coefficient that accurately reflects the severity of PCP. In
other words, the failure of APACHE II to successfully stratify patients with
AIDS was caused by APACHE II's underestimation of the severity of PCP.
Because the patient population studied by Smith et. al. was composed
exclusively of Veterans (presumably male and predominantly not
homosexual), there was some uncertainty as to the validity of the results in
respect to a more typical urban population. As well, because Smith et. al.
studied a population admitted to the MICU between January 1984 and
September 1988 (prior to improved PCP survival rates), it was felt that
another study of the application of APACHE II to HIV-positive patients
(including patients admitted after 1988 with the prospect of improved
survival from PCP) was warranted.

33

II. METHODS

Record Selection

The current study involved a review of the medical records of all HIVpositive patients admitted to the Yale-New Haven Hospital medical intensive
care unit (MICU) during a five year period. Records were selected by hospital
discharge date, between October, 1986 and September, 1991. The patients were
identified by a computerized search of patient records by the ICD-9
(International Center for Disease, ninth edition) coding of their diagnoses.
Patients were included by being identified as having either AIDS, AIDSrelated complex (ARC), HIV seropositivity, or any of the AIDS-associated
opportunistic diseases (Pneumocystis carinii pneumonia, Kaposi's sarcoma,
progressive multifocal leukoencephalopathy, or central nervous system
lymphoma, etc.). A list of 181 admissions was compiled. Eleven admission
records were either incomplete, could not be located by the medical records
department, or were otherwise unavailable for review. Of the remaining 170
records, eight were excluded because the patients had AIDS-associated diseases
though were not HIV positive and did not have AIDS or ARC. (The patients
were immunosuppressed for another reason, ie. post transplant, malignancy,
chronic high-dose steroid use). One record was excluded because the patient
was infected with HIV type II, not the usual HIV type I. One record was
excluded because the patient was found never to have been admitted to an
ICU, and two records were excluded because the patients had been admitted to
the surgical ICU, not the medical ICU. Among the 158 records remaining, it
was discovered that some patients had multiple admissions to the MICU
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which were not identified by the initial computer search. These MICU
admissions were counted as separate if they occurred during different hospital
admissions, occurred during the same hospital admission but at least four
days apart, or if the patients were admitted to the MICU for different reasons
(if the patients were placed in different diagnostic categories according to
APACHE II admission criteria). Three records fell into this last category of
being absent from the computer-generated list. Thus, in total, 161 admission
records were utilized.

Data Collection

Medical records were reviewed retrospectively between December, 1991
and June, 1992 with the approval of the Human Investigation Committee.
APACHE II data were obtained from multiple information sources in the
patients' charts including MICU admission notes, progress notes, transfer
notes, MICU nursing admission sheets, emergency room admission sheets,
emergency room transfer sheets, paramedic or ambulance transfer sheets, and
laboratory reports. In addition to information required for APACHE II
scoring, information of potential or reported prognostic value was recorded.
This included HIV risk factor, HIV diagnosis date, leukocyte counts and
differentials, CD4+ counts, orders regarding maximal supportive and
resuscitative care ("Do not resuscitate" and/or "Do not intubate" orders),
identification of microbial pathogens, serum lactate dehydrogenase levels,
number of procedural interventions, location of treatment prior to admission
to the MICU, and chest radiographic findings.
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All information necessary for APACHE II scoring was collected as
prescribed by Knaus et. al. except that we recorded the most abnormal value of
any physiologic variable beginning two hours prior to MICU admission and
ending 22 hours after MICU admission. This small change was instituted in
order to account for the previously reported problem of lead-time bias76
resulting from intensive care level services (intubation, administration of
intravenous cardiac inotropes, etc.) being delivered before the patient was
physically within the MICU (in other words, while in the ambulance, in the
emergency room, or on the floor). The only time that this did not apply was
if the pafient died within the first 22 hours within the MICU. In this case, the
earliest (though not prior to the decision to admit the patient to the MICU)
recorded variables (not the most abnormal), were used for the calculation of
the APACHE II acute physiology score. (Otherwise, heart rate, blood pressure,
respiration rate, and Glascow coma scale would need to be recorded as zero,
thus overestimating severity of illness.) Based on past reports,77'7^ and in the
method of Knaus et. al.,79 if any acute physiologic variable recordings were
not available, it was assumed that the variable fell with in the normal range.
Although APACHE II was developed as a prospective scoring system,
our time constraints made retrospective chart review more feasible for our
study. Thus, our data collection differed from the manner used by Knaus et
al. during the validation study for APACHE II. However, in order to
maintain agreement with the validation study, we only recorded data which
was prospectively available. This was done by relying on information
provided by the patient's bedside clinicians as the primary data for diagnostic
category assignment. However, in event that the patient's physician did not
clearly indicate a primary diagnosis, we would assign a diagnostic category
based on prospectively available information (information which was
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available two hours prior to or within the first twenty-two hours of MICU
admission) and assisted by decisionmaking algorithms.
The circumstance in which clinicians did not specify a primary
diagnosis was not unusual. Typical of these cases were patients being
admitted with such diagnoses as "hypotension, fever, short of breath", or
"questionable pneumonia, rule out sepsis," or "dyspnea, fever, rule out
congestive heart failure versus pneumonia," or

"abdominal pain, fever,

questionable sepsis versus gastrointestinal perforation." For these situations,
prospectively available (available to the original clinician) clinical
information such as previous sputum and blood culture results, concurrent
Swan-Ganz catheter readings, and the presence or absence of free air on an
upright abdominal X-ray was used. This is not to say that the actual bedside
clinician's prospective clinical judgment was ever ignored. We assigned
diagnostic categories only if the initial clinical assignment of diagnosis was
unclear or ambivalent.
In instances of similar and frequent clinical situations, in order to
facilitate the consistent assignment of diagnostic categories, guidelines were
established (as suggested by Knaus et. al.)80 so as to eliminate variation in our
retrospective decisionmaking process. This was done to clarify three clinical
scenarios. One involved the assignment of a diagnostic category to seizure
patients being admitted to the MICU. If the patient was intubated and
mechanically ventilated in the MICU (in the setting of a prior or ongoing
seizure), the patient was categorized as a post respiratory arrest patient. If the
patient was not intubated due to the prior seizure, though still transported to
the MICU for observation and monitoring of his or her neurologic and
respiratory status, then the patient was categorized as a seizure patient.
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A second situation in which decisionmaking criteria were established
involved the distinction between the diagnostic categories of "respiratory
infection" and "sepsis." (In this study, every patient who had a "respiratory
infection" had pneumonia.

Thus, for the remainder of this report, this

diagnostic category will be referred to as "pneumonia.") In this situation, as
usual, the patients' prospective clinical diagnosis was considered first and
foremost. If a question still remained as to the correct diagnostic
categorization, prospectively-available lab results were next considered, and
in instances of continuing uncertainty, systolic blood pressure (SBP) and
alveolar-arterial oxygenation gradient (AaPCb) was examined. In general,
previously positive blood cultures, a low SBP (< 90 mm. Hg.), and low AaPCb
were factors increasing the probability that the patient would be categorized as
septic. Conversely, negative blood cultures, a SBP > 90, and a high AaPCb led
more frequently to a disease categorization of pneumonia.
A third situation in which a guideline was established in order to
reduce inconsistency involved patients who had had emergency life support
measures taken in their behalf (patients who had been "coded"). When faced
with the decision of whether to classify a patient who had a respiratory arrest
which then progressed to a cardiac arrest, it was decided that any patient who
received intravenous cardiac inotropes, chronotropes, or mechanical
stimulation (chest compressions) would be categorized as a post cardiac arrest
patient. If the patient had a respiratory arrest (was subsequently intubated and
ventilated) yet did not require nor receive cardiac inotropes he or she would
be categorized as a respiratory arrest patient.
In order to consistently evaluate and determine the chronic health
status of individual patients, we established a guideline for immunologic
status assessment. This was done because it was felt that not all HIV-positive

38

patients admitted to the MICU were significantly immunocompromised nor
would their HIV seropositivity greatly effect their survival from their acute
illness and hospitalization. Examples of this situation are numerous:

a

recently diagnosed and asymptomatic HIV-positive patient admitted to the
MICU because of a non-immunologically related illness, such as an asthmatic
crisis, a self-administered drug overdose, or trauma. The guidelines are as
follows: The patient was felt to be immunologically compromised (and given
points for a chronic disease history) if (1) he/she were HIV-positive and had a
history of Pneumocystis carinii pneumonia (PCP), Kaposi's sarcoma (KS),
cytomegalovirus (CMV) retinits, cryptococcal meningitis, or any other AIDSdefining disease, (2) he/she were HIV-positive for 24 months or longer, (3)
he/she were diagnosed as HIV-positive at least one month prior to hospital
admission, and he/she were admitted to the hospital or MICU due to
infection, lymphoma, cachexia, or an immunologically mediated illness.
Conversely, if the patient were diagnosed as HIV-positive for less than 24
months, without a history of an AIDS-defining illness, and were admitted to
the hospital with a non-immunologically mediated illness, then he/she was
felt to be non-immunocompromised and therefore did not receive any
chronic health points (unless for other organ system failure). Using this
"immunosuppression guideline", 151 patients were given "chronic health
points" for having either a history of severe organ system insufficiency or
immunosuppression prior to hospital admission.
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Data Analysis and Statistical Methods

Medical record information was collected on data entry sheets and
transferred into a data management information system (Reflex® and
Quatrop^o® software). This software was capable of performing all needed
data retrieval and sorting functions. Data are expressed anci analyzed so as to
facilitate easy comparison with previously published APACHE II data. In
general, means are expressed ± the standard deviation (SD). Predicted
mortality risk was calculated using the APACHE II multiple logistic
regression equation. The significance of differences among groups of
continuous variables was determined by the unpaired Student's t-test and by
Chi-square tests or binomial distributions for groups of dichotomous
variables. Statistical significance is defined as p <0.05, unadjusted for
multiple comparisons.

ILL RESULTS

The patient population, represented by the 161 patient records (which
for the matter of discussing patient demographics will be considered to
represent 161 patients) consisted of 43 women and 118 men. The mean age of
the population was 37 years old (S.D.= 8.7), with a range from 21 to 79 years
old. The racial mix of the group was 92 Blacks, 14 Hispanics, 54 Whites, and 1
Native American (Table 7). The vast majority (97%) of the patients were
nonsurgical admissions. Most patients were transferred to the MICU from
either the emergency room or from another hospital floor (Figure 4). During
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the five years of this study, the number of HIV-positive patients who were
admitted to the MICU fluctuated without a clear relationship to the total
number of HIV-positive patients who were admitted to the hospital.
The population's HIV risk factors were summarized. Of the total 161
patients, 107 patients (66%) had a history of intravenous drug use (IVDA), 34
patients (21%) had a history of homosexual activity, 9 patients (6%) had a
history of both IVDA and homosexual activity, and 29 patients (18%) denied
both HIV risk factors (Table 7). Of the 29 patients without either risk factor,
many had become HIV infected by known sources or by known risks: as a
recipient of infected blood, or through sexual contact with a high risk partner
(ie., a known IV drug user, a known HIV-positive partner, or a prostitute).
It was observed that the risk factors associated with HIV infection
varied according to patients' sex and race. A history of IVDA was greatest in
black males (84%), hispanic males (82%), and white women (90%).
Homosexual activity, known not to be an HIV risk factor for women, was, as
expected, confined to the male population.

Within the male population,

homosexual activity accounted for a larger degree of HIV transmission in the
whites than in other races (White: 45%, Black: 19%, Hispanic: 18%) (Table 7).
IVDA was an equal factor leading to HIV infection among both females and
males (72% vs. 71%).
The classification of the population according to disease category
showed a predominance of MICU admissions due to infection (78 patients,
48%), either in the form of pneumonia (44 patients, 27% of the total
population), septic shock (29 patients, 18%), or a neurologic infection (5
patients, 3%) (Figure 5). Other not uncommon diagnoses were
gastrointestinal bleeding (15 patients), cardiac arrest (9 patients), self¬
intoxication (7 patients), respiratory arrest (6 patients), seizure (5 patients) and
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electrolyte/acid-base disturbance (5 patients). The remaining 50 patients were
assigned one of the other thirty diagnostic categories. Changes in disease
presentation over time were not statistically significant (data not shown).
Regarding initial severity of illness, the population's mean APACHE II
score was 20.0 (S.D. = 8.63), the median was 19, the range was from 1 to 45, and
the distribution of scores reached its zenith between 15 and 19 (Figure 6). The
population's severity of illness (as reflected by APACHE II scores) over the
five year period of study did not show statistically significant changes (data
not shown).
Regarding APACHE II's prognostic capability, APACHE II had a correct
outcome classification rate (with a mortality prognosis > .50 implying
predicted death) of 67.1%. This correct classification rate was not markedly
improved using a wide range of cutoff points (Table 8). A receiver operator
characteristics (ROC) curve was constructed based on sensitivity and
specificity values. (Figure 7).
When the APACHE II prognostic scoring system was applied to the
entire cohort population, APACHE II significantly underestimated the inhospital mortality rate (35.5% estimated (E) vs. 44.1% observed (O), p < .025).
However, this discrepancy was largely explained by the fact that APACHE II
underestimated mortality in patients with pneumonia (n=44) (28.5% (E) vs.
50.0% (O), p < .005) (Table 9 and Figure 8). In patients without pneumonia
(n=117), APACHE II correctly estimated mortality (38.1% (E) vs. 41.9% (O)).
the second largest disease category, sepsis (n=29), APACHE II slightly
overestimated mortality in patients with sepsis though this was not
statistically significant (56.4% (E) vs. 41.3% (O)).
Because Smith et. al. reported that APACHE II underestimated
mortality in patients with Pneumocystis cnrinii pneumonia (PCP),59 we

In
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investigated whether APACHE II underestimated mortality in patients with
pneumonia of any etiology or only due to P. cnrinii.

In our 44 patients with

pneumonia, the most common organism isolated was Pneumocystis cnrinii::
19 patients (43%) were identified to have been solely infected with P. cnrinii
and 7 patients had polymicrobial infections with P. cnrinii (Figure 9). In the
other 18 patients with pneumonia, 11 patients had other pathogens identified,
and 7 patients never had a pathogen identified. Common pathogens, beside

P. cnrinii, were Staphylococcus nureus, Streptococcus pneumonine,
cytomegnlovirus (CMV), and Hnemophilus influenzn.
The manner in which the respiratory pathogen was identified in our
population was variable, but often the definitive diagnosis was made by
invasive means (bronchoaveolar lavage, direct lung biopsy, or tissue sample
at autopsy). Of the 44 patients with pneumonia, 27 of them (61%) had a
negative initial sputum culture and/or stain (Table 10 A).

Of the 27 patients

with negative sputum cultures/stains, 20 later had positive microbial
identification by one of the more invasive studies. Consequently, the
sensitivity of sputum culture and stain in our study population was 46% (17
of 37) and the negative predictive value of 26% (7 of 27). Much of the lack of
sensitivity is due to lack of sensitivity concerning P. cnrinii detection. Of the
26 patients with documented P. carinii infection, only 6 had P. cnrinii
identified from their sputum (17 were identified by BAL, and 3 were
identified by tissue sample, either at autopsy or direct lung biopsy). Thus, the
sensitivity of initial sputum stain and culture in identifying P. cnrinii was
only 23.1% (Table 10 B).
Because infection with P. carinii was the most prevalent cause of
pneumonia in the study population, estimated and observed mortality rates
in pneumonia patients with and without P. cnrinii infection were compared.
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APACHE II accurately predicted mortality in patients with PCP (28.2% (E) vs.
34.6% (O)) but significantly underestimated mortality in patients with
pneumonia of another etiology (28.9% (E) vs. 72.2% (O), p < .005) (Table 11 A).
Because of concern that these results were influenced by the uncertainty that
was introduced by seven patients never having a pathogen identified, we
reanalyzed the results separating these seven patients (Table 11 B). This
reanalysis yielded results which suggested that APACHE II underpredicted
mortality in both groups of patients whose pneumonia was not caused by P.
carinii (those with another pathogen identified and those who never had a
pathogen identified).
Initial data analysis demonstrated that APACHE II's capacity to predict
group mortality rates was correlated with patients' initial severity of illness
(measured by APACHE II scores). It appeared as if APACHE II accurately
predicted group mortality rates in patients with high APACHE II scores (>25),
was less accurate in patients with high mid-range APACHE II scores (20-24),
was inaccurate in patients with low mid-range APACHE II scores (15-19), and
was most inaccurate in patients with low APACHE II scores (<14) (Table 12
and Figure 10). However, after patients with pneumonia were excluded, it
was observed that the initial inaccuracy in the distribution of the lower
APACHE II scores (<14 and 15-19) disappeared (Table 13, Figure 11). However,
in patients with pneumonia, the distribution of APACHE II scores was
important. APACHE II accurately predicted mortality in pneumonia patients
with APACHE II scores > 14. In pneumonia patients with APACHE II scores <
14, predicted mortality was significantly less than observed mortality (Table
14, Figure 12).
Similar to the inaccuracy of APACHE II in predicting mortality in
patients with pneumonia, mean APACHE II scores proved unable to
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differentiate between survivors (S) and nonsurvivors (NS) with pneumonia
(18.9 (S) vs. 21.5 (NS)) (Table 15). In all other patients, survivors' mean
APACHE II score was significantly lower than the mean score in
nonsurvivors (17.3 (S) vs. 26.3 (NS), p < .005 ).
During the evaluation of outcomes, unanticipated differences in
survival were observed in patients with pneumonia. Patients with PCP had a
significantly greater survival rate than patients with pneumonia of another
etiology (65.4% vs. 27.8%, respectively, p < .014) (Table 16 A). This difference
existed despite the two groups' similar initial prognoses (as measured by
APACHE II scores) and their need for respiratory support (intubation and
mechanical ventilation) (Table 17). The difference in survival rates was
basically unchanged if only intubated patients were considered (63.6% in
intubated patients with PCP vs. 26.7% in intubated patients with pneumonia
of another etiology) (data not shown).
When pneumonia patients who never had an organism identified
were separated into their own group, a difference in survival rates remained:
14.3% survival of patients with pneumonia without microbial identification,
36.4% survival of patients with non-P. carinii pneumonia, and 65.4%
survival of patients with PCP. The difference in mortality rates was
statistically significant between patients with PCP and patients with
pneumonia of unknown etiology. The difference in mortality between
patients with PCP and patients with pneumonia caused by another known
pathogen was not statistically significant (though perhaps still clinically
significant) (Table 16 B and 16 C).
The degree of immunosuppression was investigated to determine its
relationship to medical outcomes. Initially CD4+ T-cell count were recorded.
However, since only 34 of 161 patients' charts contained these values, we
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decided to use the total lymphocyte count (TLC) as our marker of
immunosuppression. This was in accordance with a report that TLC is an
accurate measure of CD4+ counts.81 TLC was calculated for each patient using
the following formula: TLC = # of White blood cells (WBC's) x % of WBC's
which were lymphocytes (lymphocyte differential). In the total cohort of 148
patients with adequate information, a TLC < 200 was significantly associated
with increased mortality (p = .003) (Table 18 A). Because it was postulated that
TLC would be most significantly associated with mortality rates in patients
with infection, we reanalyzed the data separating patients with either
pneumonia or sepsis. A TLC < 200 was found to be significantly associated
with increased mortality in patients with infection (p = .003) but not
significantly associated with outcome in all other patients (without
pneumonia or sepsis) (p = .105) (Table 18 B and 18 C). When the patients with
infection were separated into their original diagnostic categories (pneumonia
or sepsis), it was observed that TLC < 200 was significantly associated with
mortality in pneumonia patients. In patients with sepsis, although TLC < 200
was positively correlated with increasing mortality, it was not statistically
significant (Table 18 D and 18 E).
In addition to assessing the effect of TLC on survival, we studied
APACHE IBs predictive accuracy in relation to the location of treatment prior
to admission or transfer to the MICU. Estimated and observed mortality were
analyzed for patients in the two largest patient groups: those patients
admitted from the emergency room (n=81) and those transferred from other
hospital floors (n=72). APACHE II accurately estimated mortality in patients
admitted from the emergency room (37.6% (E) vs. 44.4% (O)), but significantly
underestimated mortality in patients transferred from other hospital floors
(33.3% (E) vs. 44.4% (O), p < .05) (Table 19).
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Because AIDS has focused so much attention on ICU utilization and
cost issues, APACHE II's accuracy relationship to patients' length of stay (LOS)
in the MICU was evaluated. The cohort had a mean MICU LOS of 7.3 ± 15.0
days (± SD). In respect to mortality, it was found that APACHE II correctly
estimated mortality in the 144 patients with a MICU LOS < 14 days (34.9% (E)
vs. 40.3% (O)) but underestimated mortality in the 17 patients with a MICU
LOS > 14 days (41.0% (E) vs. 82.4% (O), p < .005) (Table 20).

IV. DISCUSSION

This study was undertaken in order to evaluate the APACHE II
prognostic scoring system when applied to an HIV-positive population
admitted to the MICU. It was observed that APACHE II significantly
underestimated mortality in the HIV-positive population to which it was
applied. This discrepancy, however, was due to a selective underestimation
of mortality among patients with pneumonia.

In patients without

pneumonia, APACHE II accurately predicted mortality. Interestingly,
although APACHE II underestimated mortality in patients with respiratory
infection (pneumonia), it correctly predicted (in fact, slightly overestimated)
mortality in patients with systemic infection (sepsis).
The results of this study both agree with and conflict with results
previously reported by Smith et. al.. Both studies found that APACHE II
significantly underestimated mortality in HIV-positive patients.

As well,

both studies found that mean APACHE II scores were significantly different
between survivors and nonsurvivors in patients not diagnosed with
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pneumonia. However, our results differ from those reported by Smith et. al.
in the explanation given for APACHE IPs shortcomings.

Whereas Smith et.

al. reported that APACHE IPs inaccuracy is caused by underestimating
mortality in patients with PCP,59 our results indicate that APACHE IPs
inaccuracy in HIV-positive patients is due to an underestimation of mortality
in patients with pneumonia, particularly in patients with non-Pneumocystis
carinii pneumonia (NPCP). In this study, APACHE II correctly predicted
mortality among patients with PCP.
This conflict between our results and those of Smith et. al. may be
related to the difference in observed PCP mortality rates between the two
studies. Smith et. al. studied a population of PCP patients with a mortality
rate of 86.5% while the current study's PCP patients had a mortality rate of
only 34.6%.
The lower mortality rate of our study is likely related to three factors.
First, the PCP patients in this study were not as acutely ill as the patients
studied by Smith et. al. (as determined by differences in predicted mortality
rates, 28.2% vs. 45.8%, respectively). This may be due to differences in
protocol between Yale-New Haven Hospital (YNHH) (the hospital in this
study) and the New York Veterans Administration Medical Center
(NYVAMC) (the hospital in the study by Smith et. al.). For instance, the
threshold of illness which engendered a patient to be transferred to the MICU
may have been much lower at YNHH than at the NYVAMC. Therefore, the
patients included in this study would be less severely ill than those patients
included in the study by Smith et. al.
Second, because the patients in this study were admitted to the MICU
later in the "AIDS epidemic," (October 1986 to September 1991), they could be
expected to have lower mortality rates based solely on the trend toward better
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outcomes in PCP patients. Whether the decreased mortality rates are due to
better treatments for both P. carinii infection and HIV infection (ie.,
pentamidine and AZT) or to a decreased virulence of P. carinii is not known.
And third, a selection bias probably exists. Because data was
retrospectively collected in both studies, the assignment of diagnostic
categories was based on the judgment of the patients' bedside clinicians.
However, in this study and presumably in the study by Smith et. al., clinicians
often would not clearly site a specific diagnosis. In this study, diagnoses of
"pneumonia, rule out sepsis" were not uncommon in the admitting orders to
the MICU. Thus, the data collector was forced to make a decision based on the
available information. However, in such decisionmaking circumstances as
this, APACHE II does not provide data collectors with detailed guidelines
concerning the classification of disease. Hence, the assignment of diagnostic
categories was influenced by the judgment of the data collector.
Consequently, it is possible that the assignment of patients into the
disease categories of "pneumonia" and "sepsis" was done differently during
the two studies. In this study, out of 161 patients, 44 were classified as
"pneumonia" and 29 were classified as "sepsis." In the study by Smith et. ah,
out of 83 patients, 54 were classified as "pneumonia" and only 6 were
classified as "sepsis." Thus, in this study, the ratio of patients with
pneumonia to those with sepsis was 1.5 whereas in the study by Smith et. al.
the ratio was 9.0. This difference (1.5 vs. 9.0) in the ratio of patients with
pneumonia to those with sepsis may reflect an actual difference in the MICU
populations at the different institutions. However, it seems more likely (as
will be discussed below) that this difference is due to the manner in which
patients were assigned to diagnostic categories. Therefore, the observed low
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rate of mortality in PCP patients in this study may be partially due to the
presence of selection bias.
Although the disagreement between this study's results and those of
Smith et. al. may partially be explained by the difference in PCP mortality
rates observed during the two studies, the difference in mortality rates
between the two studies does not explain why APACHE II underestimated
mortality in all patients with pneumonia in this study. The possible
explanation for the underestimation of mortality in pneumonia patients is
threefold. First, as discussed in relation to PCP mortality rates, there is likely
to be a selection bias affecting all patients with pneumonia. Because the
APACHE II prognostic scoring system does not provide decisionmaking
algorithms concerning the assignment of diagnostic categories, individual
data collectors must make these decisions on their own.

This decision enters

into the calculation of predicted mortality using the APACHE II multiple
logistic regression equation (See below). Thus, the absence of decisionmaking
algorithms for the categorization of disease directly influences the predicted
mortality rate and the prognostic accuracy of the APACHE II system.

APACHE II multiple logistic regression equation
In (R/l-R)= -3.517+ .146 (APACHE II score)+ DCW + .603 {only if
emergency postoperative},
R=Risk of death and DCW= Diagnostic category weight

The lack of algorithms is especially significant for patients whose
APACHE II scores fall in the middle range of scores. When the APACHE II
score is either low or high, the relative importance of diagnostic categories is
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small.

Within the middle range of scores, however, variations in disease

classification greatly affect calculated risk predictions. (This is a direct
consequence of the logistic structure of the regression equation and has been
confirmed by Knaus et. al. regarding APACHE III.45)
The conclusion that the APACHE II predicted morality calculations are
subject to interobserver variation in the assignment of diagnostic categories
has been previously reported. Jackson et. al. found a large degree of inter¬
observer variation in the assignment of diagnostic categories for a small test
population.83 In the assessment of disease, the four participants in the study
agreed on the disease categorization in only four of the ten patients. Concern
about interobserver reliability (and intraobserver reliability) in the
determination of precipitating factors of ICU admission has also been
expressed by Teres and Lemeshow 42'84
To further complicate the issue of categorizing a patient with
pneumonia versus one with sepsis is the lack of consensus regarding the
definition of sepsis.

Working definitions of the terms "bacteremia,"

"septicemia," "sepsis," "sepsis syndrome," and "septic shock" have been
offered,85 but it is unlikely that they are clinically differentiated in the same
manner at separate institutions. Consequently, individual clinicians and data
collectors involved in one study are not likely to be categorizing patients'
diseases in the same way as individuals involved in a similar study at
another institution.
Thus, APACHE IPs inaccuracy in predicting outcome in pneumonia
patients is likely to be partially due to an absence of precisely defined
decisionmaking algorithms, and the resulting interobserver variation
affecting disease categorization. A second potential cause of APACHE II's
underestimation of mortality in pneumonia patients is an inadequate
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adjustment for the severity of immunologic suppression by HIV.

In the

comparison of estimated and observed mortality rates in pneumonia patients
(Table 14, Figure 12), it is apparent that APACHE II's greatest degree of
inaccuracy focuses on patients with relatively low APACHE II scores and a
lesser apparent severity of acute illness. However, it is also clear that
APACHE II slightly underestimates mortality across the entire distribution of
APACHE II scores. Unlike the results of Smith et. al., which led to the
conclusion that APACHE II does not adequately adjust for the severity of PCP,
our results point to a broader deficit: an inadequate adjustment for the effects
of immunosuppression, particularly in patients with pneumonia with low
APACHE II scores.
The third factor which can potentially explain some of the discrepancy
between estimated and observed mortality in pneumonia patients is the
significant number of patients with an unknown etiology of their
pneumonia. It was observed that APACHE II significantly underestimated
mortality for these patients. This inaccuracy is likely to be the result of two
things:

first, patients with pneumonia of unknown etiology are more likely

to be infected with CMV or cryptococcus because these organisms are more
difficult to identify or culture. These patients are also known to be more
severely immunosuppressed than patients with PCP. Second, the empiric
antibiotic therapy directed at an unknown organism is likely to be less
efficacious than specific therapy directed at a known pathogenic agent. The
combination of these factors helps to explain the low survival rate of patients
with pneumonia of unknown etiology and the underestimation of mortality
for pneumonia patients as a whole.
Thus, APACHE II's underestimation of mortality in patients with
pneumonia is multifactorial. It is likely due to (1) APACHE II's lack of
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decisionmaking algorithms; (2) APACHE II's inadequate risk adjustment for
HIV infection in patients with a diagnosis indicating an infectious etiology;
and (3) a significant proportion of pneumonia patients in this study
population without a known etiologic agent for the cause of their
pneumonia.
After research on the current study was begun, three more reports
concerning APACHE II's application to patients with AIDS were published.
In 1991, Benson et. al.60 published a report which analyzed retrospectively
collected data from 72 hospitalized patients (not necessarily in the ICU) with
first-episode PCP admitted between April 1985 and December 1987. Only 12
patients required mechanical ventilation and the mortality attributable to PCP
in the total cohort was low (8 deaths). Four parameters (admission serum
albumin, serum LDH, alveolar-arterial oxygen gradient (AaP02), and the
APACHE II score) were compared for their ability to predict mortality. Serum
albumin levels, LDH levels, and APACHE II scores were significantly
different between the group of survivors and the group of nonsurvivors. In a
stepwise discriminant analysis, only APACHE II score and serum LDH levels
were statistically associated with mortality.
Benson's conclusion, namely that the APACHE II score is one of the
measures which was significantly associated with mortality in patients with
PCP, is in frank disagreement with the results previously reported by Smith
et. al. but is in agreement with the present study's conclusions. This is likely
a function of either one or both of the following:

the improved survival of

patients with PCP during the latter 1980’s, and the initial severity of acute
illness (as described by the predicted mortality rates and the need for
mechanical ventilation) (Table 21).
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Table 21: Characteristics of Patients with PCI’ in the Different Studies
which have Applied APACHE II to AIDS
Predicted
Mortality (%)

Observed
Mortality (%)

Author

Time frame
of Stud v

% needing MV

Smith

1/84 - 9/88

76% (41 /54)

44.3*

86.5*

Benson

1/85-12/87

16% (12/75)

14.4**

16.0

Current study

10/86-9/91

85% (22/26)

28.2

34.6

This value is based only on those 37 patients who had PCP requiring mechanical ventilation.
Predicted and observed mortality rates for patients with other types of pneumonia were not
reported.
** This value was calculated from the reported mean APACHE 11 scores.
MV= mechanical ventilation

Another study concerning APACHE II's application to patients with
AIDS was presented in the literature in the form of an abstract.61 jiva et. al.
studied 76 AIDS patients with successive hospital admissions. In 1991, they
reported that there was a positive correlation between APACHE II scores and
mortality in AIDS patients. However, it was noted that observed mortality
was higher at every APACHE II score for patients with AIDS than that
reported for patients without AIDS. Thus, the APACHE II prognostic scoring
system, though correlated with mortality outcome, underpredicted mortality
in patients with AIDS. Unfortunately for the sake of comparison with the
current study, the percentage of the study population that was categorized as
having pneumonia was not reported.
The final study, published in 1992 by Montaner et. al.,62 compared the
association of the APACHE II score, the acute lung injury (ALI) score, the
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AIDS Prognosis score, the modified multi-system organ failure (MSOF) score,
and serum LDH with mortality in patients with PCP. The patient population
was comprised of 52 ICU admissions between January 1985 and April 1991. 47
patients (90%) required mechanical ventilation, and the mortality of this
group was 72%. In the 5 patients who did not receive mechanical ventilation,
4 died (80%). The results of the study indicate that the MSOF score was the
only independent predictor of mortality, though there was a positive
correlation between mortality and both MSOF score and serum LDH. The
AIDS Prognostic Staging System, the ALI score, and the APACHE II prognostic
scoring system were found to be poor prognostic tools in this group of
patients with AIDS.

Montaner et. al. conclude that "it is not the severity of

lung injury that predicts mortality [in patients with PCP], but rather the extent
of multisystem organ failure." It is unclear whether this conclusion has
validity in other patient groups. It appears that Montaner et. al. believe that
survival among critically ill patients is dependent not only upon the severity
of physiologic abnormality caused by dysfunction in a primary organ system,
but also upon the degree of other organ system compromise or impairment.
Although Montaner's results concerning the prognostic accuracy of
APACHE II when applied to patients with PCP conflict with the present
study's results, Montaner's conclusion appears to make good clinical sense in
that patients with mulitsystem organ failure may be expected to have a high
mortality rate.86 Because the APACHE II prognostic scoring system was
designed to account for only one factor precipitating admission to the ICU, it
is systematically unable to accurately adjust for mortality risk in patients with
multisystem organ failure. It can be argued that all AIDS patients with
pneumonia requiring mechanical ventilation and/or intensive care
monitoring have at least two organ systems in failure: respiratory and
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immunologic. However, APACHE II is only designed to account for
pneumonia as a factor necessitating ICU admission whereas it accounts for
immunologic insufficiency in Chronic Health Status.

Concern for the

accuracy of APACHE II in patients with multisystem organ failure is
especially relevant in AIDS patients because of the complexity of disease
manifest by AIDS patients. Consequently, patients with AIDS may have
outcomes (survival versus nonsurvival) that are not primarily caused by the
initial disease process which precipitated MICU admission.
The observation that multisystem organ failure presents difficulties to
the APACHE II system was acknowledged by Knaus and his colleagues when
they stated that "[i]t may be difficult in patients with multi-system failure to
decide which system failure is primary and which is secondary, etc. Your best
clinical judgment is to be used to make the decision; and if two systems are
assessed to be 'equal' in failure, one system can be 'arbitrarily' indicated as
primary."80
Thus, Montaner’s results imply that in patients with pneumonia and
known severe immunosuppression, APACHE II is inaccurate because it does
not adequately account for multisystem organ failure and, thus, should be
expected to underestimate mortality rate. This conclusion is somewhat
supported by our findings that TLC < 200 is strongly associated with
increasing mortality in patients with pneumonia.

In addition, this finding

may help explain why, in this study, APACHE II so greatly underestimated
mortality in patients with pneumonia and low APACHE II scores. Perhaps
the group of pneumonia patients with low APACHE II scores who did not
survive hospitalization were actually more severely immunocompromised
(TLC < 200) than those who survived. Although the cause of this discrepancy

is uncertain, the degree of "unaccounted" immunosuppression may be of
explicative value.
Our results indicate that APACHE II's accuracy in predicting mortality
rates varies according to the treatment location prior to admission to the
MICU. APACHE II accurately estimated mortality in patients admitted from
the emergency room, but significantly underestimated mortality in patients
transferred from other hospital floors. This confirms the results previously
reported by Escarce.66
In respect ICU utilization, our results indicate that the accuracy of
APACHE II's estimated mortality rates was dependent on the length of stay
(LOS) of patients in the MICU. APACHE II correctly estimated mortality in
patients with a MICU LOS < 14 days but underestimated mortality in patients
with a MICU LOS > 14 days. This difference between mortality rates according
to length of stay in the MICU supports the finding of a similar difference
recently reported concerning very old patients (>80 years) who were being
mechanically ventilated in the MICU.82
Although the APACHE II system has received its share of criticism,
many of the weaknesses of APACHE II have been acknowledged by Knaus et.
ah, and aPACHE II was subsequently modified to incorporate some necessary
changes. The result of these changes was the APACHE III prognostic scoring
system which was validated on a cohort of 17,440 patients.45 The APACHE III
prognostic scoring system, as expected, is based on the same conceptual
approach as the original APACHE system and APACHE II. However, changes
were made in selecting and weighting the physiologic variables which
determine the acute physiology score (more variables were chosen, and the
weights have a greater range). The concern for lead-time bias in terms of
location and duration of treatment prior to ICU admission has been
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addressed. The number of diagnostic categories was expanded from fifty-three
to seventy-eight, allowing for more precision in the categorization of disease,
and the diagnostic category weights were revised. As well, the determination
of physiologic reserve was reworked. The age assessment has been re¬
weighted and the list of significant comorbid conditions has been
substantially redefined (only those comorbid conditions which influenced
patients' immunologic status were found to be significant upon statistical
analysis).
At present, the published results of APACHE III indicate that its overall
explanatory power is greater than that of APACHE II. However, in relation to
our study, its accuracy when applied to an HIV-positive population and
specificcdly to HIV-positive patients with non-Pneumocystis carinii
pneumonia has not been independently validated. This is one area which
warrants future research, particularly in relation to patients with pneumonia
(either PCP or NPCP). As well, our results indicate that some measure of the
severity of immunosuppression (if available, CD4+ T-cell counts; if not
available, then total lymphocyte count) may provide added prognostic
accuracy to the APACHE II (and possibly the APACHE III) system. This
deserves to be studied, particularly in regard to HIV-positive patients with
pneumonia whose APACHE II scores fall in the low range of the distribution.
In conclusion, our results indicate that the APACHE II prognostic
scoring system is not an accurate method of stratifying HIV-positive MICU
patients with pneumonia (particularly NPCP) in respect to in-hospital
mortality. When applied to HIV-positive patients without a diagnosis of
pneumonia, however, APACHE II proved to be an accurate method of
estimating mortality and risk adjustment. The reason for APACHE IPs
underestimation of mortality is multifactorial. It is likely to be due, at least
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partially, to (1) inadequate adjustment for the severity of immunologic
suppression in patients with a diagnosis indicating an infectious etiology of
their illness; (2) lack of precisely defined decisionmaking algorithms to aid in
the assignment of disease categories; and (3) a significant proportion of HIV¬
positive patients with pneumonia of unknown etiology who may be
uniquely resistant to treatment. The use of TLC as an additional risk factor
may improve predictive accuracy of ICU risk adjustment models for use in
HIV-positive patients with diagnoses of infection.

Eigure 3; The APACHE II Prognostic Scoring System

Figure 4:
00

80

60

40

20

0

Location prior to MICU

Figure 5:

Diseases Precipitating

# of Patients

MICU Admission

Distribution of APACHE SI Scores

of Patients

Figure 6:

APACHE II Scores

Receiver Operator Characteristics Curve

Sensitivity

Figure 7

1-Specificity

Figure 8:

Estimated vs. Observed Mortality
by Disease Category

>*

03

k.
O

Pneumonia

Disease Category

Not Pneumonia

m

Estimated Mortality

□

Observed Mortality

Figure 9:

Pathogens Causing Respiratory Infection
in HIV-Positive Patients Admitted to MICU

4 3%

|

No organism identified

553

P. carinii

II

P. carinii plus others

E3

Single organism, not P. carinii

□

Polymicrobial, not P. carinii

Figure 10:

Estimated vs. Observed IVlortaSity

APACHE IS Scores

Rates

Figure 11:

Estimated vs. Observed Mortality Rates,
Excluding Patients with Pneumonia

Figure 12:

Estimated vs. Observed Mortality Rates
in Patients with Pneumonia

APACHE !l Scores

Table 7: Population Demographics: Sex, Race, and HIV Risk Factors

HIV Risk
Factor

IVDA* (N=98)

Men
_(N=118)_
B
H
W
NA

Women
(N=43)
B
H

W

45

8

13

1

20

2

9

Activity** (N=25)

5

1

19

0

0

0

0

Both+ (N=9)

7

1

1

0

0

0

0

Neither"*’"*’ (N=29)

5

1

11

0

10

1

1

Homosexual

’*’
"*”*"

History of intravenous drug abuse, no history of homosexual activity
History of homosexual activity, no history of IVDA
History of both IVDA and homosexual activity
History of neither IVDA nor homosexual activity

B= Black
H= Hispanic
W= White
NA= Native American

Table 8: APACHE II's Accuracy in Outcome Prediction and Statistical Power

Cutoff Point
> .10
> .20
> .30
> .35
> .40
> .45
> .50
> .60
> .70
>.80
> .90

Sensitivity*
94.4
80.3
66.2
57.7
53.5
53.5
43.7
36.6
26.8
18.3
9.9

All numbers are percentages

Specificity*
24.4
46.6
70.0
77.8
80.0
81.1
85.5
92.2
93.3
98.9
100

PPV*

NPV*

49.6
54.3
63.5
67.2
67.8
69.1
70.5
78.8
76.0
92.9
100

84.6
75.0
72.4
70.0
68.6
68.9
65.8
64.8
61.7
60.5
57.0

% Co
55.2
61.4
66.4
68.9
68.3
68.9
67.1
67.7
64.0
63.4
58.3

Table 9: Estimated vs. Observed Mortality by Disease Category

Disease Cateeorv

N

Estimated
Observed
Mortality (%) Mortality (%)

X2

p value
(d.f.= 1)

161

35.5

44.1

5.19

< .025

44

28.5

50.0

9.98

< .005

117

38.1

41.9

.709

NS

Sepsis

29

56.4

41.3

2.67

NS

Pneumonia or Sepsis

73

39.6

46.6

1.48

NS

Neither Pneumonia
nor Sepsis

88

32.2

37.5

1.13

NS

All
Pneumonia
Not Pneumonia

Table 10 A: Accuracy of Sputum Stain and Culture for the Identification of
Pathogens in HIV-Positive Patients with Pneumonia

Sputum
test results

Pathogen
identified

No pathogen
ever identified

Positive

17

0

Negative

20

7

*

* A-

Sensitivity= 17/37= 46%
Negative Predictive Value= 7/27= 26%
False Negative Rate= 20/27= 74%

For the calculation of sensitivity, all positive sputum cultures/stains are assumed to be
accurate.
** For the calculation of negative predictive value, patients who never had a pathogen
identified were assumed to not be microbially infected.

Table 10 B: Accuracy of Sputum Stain and Culture for the Identification of
Pneumocystis carinii in HIV-Positive Patients with Pneumonia

Sputum
test results
Positive
Negative

Documented*

P. car in ii
6
20

Sensitivity= 6/26= 23%

P. carinii, if not documented by sputum sample, was later identified by bronchoalveolar
lavage, open lung biopsy, or at autopsy.

Table 11 A: Estimated vs. Observed Mortality for Patients with Pneumonia

Type of

Estimated

Observed

Mortality (%)

Mortality (%)

Pneumonia

N

X2

PCP

26

28.2

34.6

0.53

NPCP

18

28.9

72.2

16.45

p value

NS
< .005

PCP= Pneumocystis cnrinii pneumonia
NPCP= Non-Pneumocystis carinii pneumonia

Table 11 B: Estimated vs. Observed Mortality for Patients with Pneumonia

N

PCP

■26

28.2

34.6

0.53

Other pathogen

11

23.2

63.6

_*

= .005

7

37.8

85.7

_*

= .014

No pathogen
identified

Estimated

Observed

Mortality (%)

Mortality (%)

IX
N>

Type of
Pneumonia

p value

NS

PCP= Pneumocystis cnrinii pneumonia
* Signifies that statistical significance was calcutated using a binomial
distribution (1-tailed)

Table 12: Estimated vs. Observed Mortality by APACHE II Scores

Estimated
APACHE II Score

All

N

Observed

Mortality (%) Mortality (%)

x2

p value

161

35.5

44.1

5.19

< .025

< 14

45

11.2

24.4

7.94

< .005

15-19

43

24.2

37.2

3.97

< .05

20 - 24

28

39.1

46.4

0.63

NS

>25

45

68.5

68.9

.003

NS

Table 13: Estimated vs. Observed Mortality by APACHE II Scores, Excluding
Patients with Pneumonia

Estimated
APACHE II Score

N

Observed

Mortality (%) Mortality (%)

p value
X2

(d.f.= 1)

All

117

38.2

41.9

0.67

NS

< 14

30

10.0

10.0

0.00

NS

15-19

25

21.3

36.0

3.28

NS

20-24

21

37.1

42.9

0.29

NS

> 25

41

69.6

68.3

0.03

NS

Table 14: Estimated vs. Observed Mortality by APACHE II Scores in Patients
with Pneumonia

Estimated

Observed

x2

APACHE II Score

N

All

44

28.5

50.0

9.98

< .005

< 14

15

13.6

53.3

_*

= .0002

15-19

18

28.2

38.9

1.02

NS

20-24

7

45.1

57.1

_*

NS

> 25

4

57.2

75.0

_*

NS

Mortality (%) Mortality (%)

* Signifies that statistical significance was calculated using a binomial
distribution (1-tailed)

p value

Table 15: APACHE II Scores for Survivors and Nonsurvivors

Average APACHE II Scores ± S.D.
Disease Category

Survivors (N)

Nonsurvivors (N)

Pneumonia

16.5 ±4.5

(22)

17.5 ±5.9

Not Pneumonia

17.3 ±6.9

(68)

26.3 ±10.3 (49)

(22)

p value

NS
< .005

Table 16 A: Mortality in Patients with Pneumonia

Survivors
PCP

Observed
Survival (%)

Non-Survivors

17

9

65.4

5

13

27.8

NPCP

X2 = 6.018

p = 0.014

Table 16 B: Mortality in Patients with PCP vs. Pneumonia of Unknown
Etiology

Survivors
PCP
Unknown etiology

Non-Survivors

Observed
Survival (%)

17

9

65.4

1

6

14.3

Fischer Exact test (2 tailed); p = .030

Table 16 C: Mortality in Patients with Pneumonia, Excluding Patients
without a Known Etiology of the Pneumonia

Survivors
PCP
Other identified pathogen

Non-Survivors

Observed
Survival (%)

17

9

65.4

4

7

36.4

Fischer Exact test (2 tailed); p = .151

PCP= Pneumocystis carinii pneumonia
NPCP= Non-Pneumocystis carinii pneumonia

Table 17: Severity of Illness in Patients with PCP vs. Non-PCP Pneumonia

PCP (n=26)

NPCP (n=18)

p value

Requiring
Intubation (%)

85

83

NS

Mean APACHE II
Score

16.9 ±5.0

17.1 ±5.5

NS

Predicted
Mortality (%)

28.2 ± 13.8

28.9 ± 15.4

NS

PCP - Pneumocystis carinii pneumonia
NPCP =Non-Pneumocystis carinii pneumonia

Table 18: Association between Total Lymphocyte Count (TLC)* and Mortality

TLC

# of Survivors

# of Non-survivors

jf.
A. Total Population
< 200

14

22

>201

75

37

Chi-square = 8.96
p = .003

B. Pneumonia or Sepsis
<200

2

12

>201

31

21

Chi-square = 9.07
p = .003

C. Not Pneumonia nor Sepsis
<200

12

10

>201

44

16

Chi-square = 2.62
p = .105

D. Pneumonia
<200

1

7

>201

19

13

Fischer Exact (2-tailed)
p = .048

E. Sepsis
< 200

1

5

>201

12

8

Fischer Exact (2-tailed)
p = .163

TLC was calculated using the formula TLC = # of WBC's x lymphocyte differential (%
WBC's which were lymphocytes).
3(*

Of the total population of 161 patients, 148 (91.9%) had the necessary information in their
charts for the calculation of TLC.

Table 19: Estimated vs. Observed Mortality by Location Prior to MICU

Estimated
Mortality (%)

Observed
Mortality (%)

X-

p value

Emergency Room (n=81)

37.6

44.4

1.62

NS

Hospital Floor (n=72)

33.3

44.4

4.02

< .05

Table 20: Estimated vs. Observed Mortality by MICU Length of Stay

Estimated

Observed

Mortality (%)

Mortality (%)

X2

MICU LOS < 14 days (n= 144)

34.9

40.3

1.83

MICU LOS > 14 days (n=l 7)

41.0

82.4

12.02

p value

NS
< .005
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